国产精华液1区2区区别,国产欧美日韩一级在线,日本精品1区国产精品,亚洲国产成人精品综合

KRAS-C9 is a potent and selective allosteric inhibitor of oncogenic K-Ras(G12C). It irreversibly binds to a common oncogenic mutant K-Ras(G12C) and blocks K-Ras(G12C) interactions, therefore does not affect the wild-type protein. Binding of KRAS-C9 to K-Ras(G12C) disrupts both switch-I and switch-II, subverting the native nucleotide preference to favour GDP over GTP and impairing binding to Raf. It can decrease viability and increase apoptosis of K-Ras(G12C)-containing cancer cell lines. KRAS-C9 provides structure-based validation of a new allosteric regulatory site on Ras that is targetable in a mutant-specific manner.

?

How to Use:

• In vitro:? KRAS-C9 was used at 10 μM final concentration in various in vitro assays.
• In vivo:?n/a

?

Reference:

• 1. Ostrem JM, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. (2013) Nature. 503(7477):548-51.